Company Details
intas-pharmaceuticals
18,773
855,228
3254
intaspharma.com
0
INT_1144321
In-progress


Intas Pharmaceuticals Company CyberSecurity Posture
intaspharma.comIntas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.
Company Details
intas-pharmaceuticals
18,773
855,228
3254
intaspharma.com
0
INT_1144321
In-progress
Between 750 and 799

Intas Pharmaceuticals Global Score (TPRM)XXXX



No incidents recorded for Intas Pharmaceuticals in 2026.
No incidents recorded for Intas Pharmaceuticals in 2026.
No incidents recorded for Intas Pharmaceuticals in 2026.
Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.


Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier li

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneer

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worl

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portf

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trad
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye ca
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently addre
.png)
The 16th Elets Healthcare Innovation Summit & Awards is where you prove you're serious about protecting patients, hospitals, and the $450 billion healthcare...
Intas Pharmaceuticals has announced the appointment of Dr. Pramod Kharwade as the Vice President of Formulation and Development.
Cybersecurity expert Sumeet Khokhani has joined Reliance Industries as Vice President - IRM & Cybersecurity. Before joining Reliance...
Pharma is on a roll. More than a fifth of the 100 richest billionaires in India have pharma and health care riches, among them half of the...

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of Intas Pharmaceuticals is https://intaspharma.com.
According to Rankiteo, Intas Pharmaceuticals’s AI-generated cybersecurity score is 795, reflecting their Fair security posture.
According to Rankiteo, Intas Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, Intas Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.
According to Rankiteo, Intas Pharmaceuticals is not certified under SOC 2 Type 1.
According to Rankiteo, Intas Pharmaceuticals does not hold a SOC 2 Type 2 certification.
According to Rankiteo, Intas Pharmaceuticals is not listed as GDPR compliant.
According to Rankiteo, Intas Pharmaceuticals does not currently maintain PCI DSS compliance.
According to Rankiteo, Intas Pharmaceuticals is not compliant with HIPAA regulations.
According to Rankiteo,Intas Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
Intas Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.
Intas Pharmaceuticals employs approximately 18,773 people worldwide.
Intas Pharmaceuticals presently has no subsidiaries across any sectors.
Intas Pharmaceuticals’s official LinkedIn profile has approximately 855,228 followers.
Intas Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, Intas Pharmaceuticals does not have a profile on Crunchbase.
Yes, Intas Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intas-pharmaceuticals.
As of January 22, 2026, Rankiteo reports that Intas Pharmaceuticals has not experienced any cybersecurity incidents.
Intas Pharmaceuticals has an estimated 5,507 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, Intas Pharmaceuticals has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
Backstage is an open framework for building developer portals, and @backstage/backend-defaults provides the default implementations and setup for a standard Backstage backend app. Prior to versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0, the `FetchUrlReader` component, used by the catalog and other plugins to fetch content from URLs, followed HTTP redirects automatically. This allowed an attacker who controls a host listed in `backend.reading.allow` to redirect requests to internal or sensitive URLs that are not on the allowlist, bypassing the URL allowlist security control. This is a Server-Side Request Forgery (SSRF) vulnerability that could allow access to internal resources, but it does not allow attackers to include additional request headers. This vulnerability is fixed in `@backstage/backend-defaults` version 0.12.2, 0.13.2, 0.14.1, and 0.15.0. Users should upgrade to this version or later. Some workarounds are available. Restrict `backend.reading.allow` to only trusted hosts that you control and that do not issue redirects, ensure allowed hosts do not have open redirect vulnerabilities, and/or use network-level controls to block access from Backstage to sensitive internal endpoints.
Backstage is an open framework for building developer portals, and @backstage/cli-common provides config loading functionality used by the backend and command line interface of Backstage. Prior to version 0.1.17, the `resolveSafeChildPath` utility function in `@backstage/backend-plugin-api`, which is used to prevent path traversal attacks, failed to properly validate symlink chains and dangling symlinks. An attacker could bypass the path validation via symlink chains (creating `link1 → link2 → /outside` where intermediate symlinks eventually resolve outside the allowed directory) and dangling symlinks (creating symlinks pointing to non-existent paths outside the base directory, which would later be created during file operations). This function is used by Scaffolder actions and other backend components to ensure file operations stay within designated directories. This vulnerability is fixed in `@backstage/backend-plugin-api` version 0.1.17. Users should upgrade to this version or later. Some workarounds are available. Run Backstage in a containerized environment with limited filesystem access and/or restrict template creation to trusted users.
Backstage is an open framework for building developer portals. Multiple Scaffolder actions and archive extraction utilities were vulnerable to symlink-based path traversal attacks. An attacker with access to create and execute Scaffolder templates could exploit symlinks to read arbitrary files via the `debug:log` action by creating a symlink pointing to sensitive files (e.g., `/etc/passwd`, configuration files, secrets); delete arbitrary files via the `fs:delete` action by creating symlinks pointing outside the workspace, and write files outside the workspace via archive extraction (tar/zip) containing malicious symlinks. This affects any Backstage deployment where users can create or execute Scaffolder templates. This vulnerability is fixed in `@backstage/backend-defaults` versions 0.12.2, 0.13.2, 0.14.1, and 0.15.0; `@backstage/plugin-scaffolder-backend` versions 2.2.2, 3.0.2, and 3.1.1; and `@backstage/plugin-scaffolder-node` versions 0.11.2 and 0.12.3. Users should upgrade to these versions or later. Some workarounds are available. Follow the recommendation in the Backstage Threat Model to limit access to creating and updating templates, restrict who can create and execute Scaffolder templates using the permissions framework, audit existing templates for symlink usage, and/or run Backstage in a containerized environment with limited filesystem access.
FastAPI Api Key provides a backend-agnostic library that provides an API key system. Version 1.1.0 has a timing side-channel vulnerability in verify_key(). The method applied a random delay only on verification failures, allowing an attacker to statistically distinguish valid from invalid API keys by measuring response latencies. With enough repeated requests, an adversary could infer whether a key_id corresponds to a valid key, potentially accelerating brute-force or enumeration attacks. All users relying on verify_key() for API key authentication prior to the fix are affected. Users should upgrade to version 1.1.0 to receive a patch. The patch applies a uniform random delay (min_delay to max_delay) to all responses regardless of outcome, eliminating the timing correlation. Some workarounds are available. Add an application-level fixed delay or random jitter to all authentication responses (success and failure) before the fix is applied and/or use rate limiting to reduce the feasibility of statistical timing attacks.
The Flux Operator is a Kubernetes CRD controller that manages the lifecycle of CNCF Flux CD and the ControlPlane enterprise distribution. Starting in version 0.36.0 and prior to version 0.40.0, a privilege escalation vulnerability exists in the Flux Operator Web UI authentication code that allows an attacker to bypass Kubernetes RBAC impersonation and execute API requests with the operator's service account privileges. In order to be vulnerable, cluster admins must configure the Flux Operator with an OIDC provider that issues tokens lacking the expected claims (e.g., `email`, `groups`), or configure custom CEL expressions that can evaluate to empty values. After OIDC token claims are processed through CEL expressions, there is no validation that the resulting `username` and `groups` values are non-empty. When both values are empty, the Kubernetes client-go library does not add impersonation headers to API requests, causing them to be executed with the flux-operator service account's credentials instead of the authenticated user's limited permissions. This can result in privilege escalation, data exposure, and/or information disclosure. Version 0.40.0 patches the issue.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.